Youth-onset type 2 diabetes: translating epidemiology into clinical trials

Diabetologia. 2021 Aug;64(8):1709-1716. doi: 10.1007/s00125-021-05480-w. Epub 2021 Jun 1.

Abstract

Globally, the proportion of new diagnoses of youth-onset diabetes represented by type 2 diabetes is increasing, and youth with type 2 diabetes commonly have complications and comorbidities, as well as a higher rate of mortality. In this review, we summarise what is known about the natural progression of youth-onset type 2 diabetes from published clinical trials and large-scale prospective epidemiological studies. It is important to note that the robust pathophysiological and treatment data specifically related to individuals with a diabetes onset at ≤20 years of age largely hails from the USA. Youth-onset type 2 diabetes is characterised by pathophysiological heterogeneity and inadequate glycaemic control, highlighting the need for new treatment approaches and innovative study designs in populations of varied genetic and cultural backgrounds.

Keywords: Clinical trials; Epidemiological studies; Review; Study design; Youth-onset type 2 diabetes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Child
  • Clinical Trials as Topic*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Female
  • Glycemic Control
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Life Style
  • Male
  • Metformin / therapeutic use
  • Prospective Studies
  • Rosiglitazone / therapeutic use
  • Translational Science, Biomedical*
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Insulin
  • Rosiglitazone
  • Metformin